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Abstract
Background: The accuracy of malaria diagnosis has received renewed interest in recent years due
to changes in treatment policies in favour of relatively high-cost artemisinin-based combination
therapies. The use of rapid diagnostic tests (RDTs) based on histidine-rich protein 2 (HRP2)
synthesized by Plasmodium falciparum has been widely advocated to save costs and to minimize
inappropriate treatment of non-malarial febrile illnesses. HRP2-based RDTs are highly sensitive and
stable; however, their specificity is a cause for concern, particularly in areas of intense malaria
transmission due to persistence of HRP2 antigens from previous infections.
Methods: In this study, 78,454 clinically diagnosed malaria patients were tested using HRP2-based
RDTs over a period of approximately four years in four highland sites in Kenya and Uganda
representing hypoendemic to mesoendemic settings. In addition, the utility of the tests was
evaluated in comparison with expert microscopy for disease management in 2,241 subjects in two
sites with different endemicity levels over four months.
Results: RDT positivity rates varied by season and year, indicating temporal changes in accuracy
of clinical diagnosis. Compared to expert microscopy, the sensitivity, specificity, positive predictive
value and negative predictive value of the RDTs in a hypoendemic site were 90.0%, 99.9%, 90.0%
and 99.9%, respectively. Corresponding measures at a mesoendemic site were 91.0%, 65.0%, 71.6%
and 88.1%. Although sensitivities at the two sites were broadly comparable, levels of specificity
varied considerably between the sites as well as according to month of test, age of patient, and
presence or absence of fever during consultation. Specificity was relatively high in older age groups
and increased towards the end of the transmission season, indicating the role played by anti-HRP2
antibodies. Patients with high parasite densities were more likely to test positive with RDTs than
those with low density infections.
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Conclusion: RDTs may be effective when used in low endemicity situations, but high false positive
error rates may occur in areas with moderately high transmission. Reports on specificity of RDTs
and cost-effectiveness analyses on their use should be interpreted with caution as there may be
wide variations in these measurements depending upon endemicity, season and the age group of
patients studied.
Background
Most countries in sub-Saharan Africa now recommend
first-line treatment of malaria with artemisinin-based
combination therapy (ACT). These combinations are
highly effective against drug-resistant Plasmodium falci-
parum, but are substantially more expensive than previ-
ously used drugs. Currently, ACT antimalarials are made
available in many countries through external support,
such as that provided by grants from the Global Fund to
Fight AIDS, Tuberculosis and Malaria. However, their
high cost means that their rational use is essential to
ensure sustainability.
Malaria treatment in most endemic countries in Africa is
based on clinical signs and symptoms due to lack of relia-
ble microscopy in the majority of peripheral health units.
The use of rapid diagnostic tests (RDTs) in malaria diag-
nosis is, therefore, increasing in many countries as the
result of their ease of use with minimal training [1]. In the
face of increasingly expensive malaria treatment regimens,
the introduction of RDTs in peripheral health units is
being advocated as a means of avoiding over-diagnosis of
malaria. Compared with presumptive treatment, RDTs
have been reported to be cost-effective in most parts of
Africa and they may be beneficial in reducing inappropri-
ate treatment of non-malarial febrile illnesses, in particu-
lar bacterial infections [2].
The diagnostic accuracy of RDTs can vary substantially
across different geographical areas making it difficult to
compare results from studies conducted under non-stand-
ard conditions [3]. RDTs that detect the histidine-rich pro-
tein 2 (HRP2) antigen (which is uniquely synthesized by
P. falciparum) have been recommended in endemic areas
where this species is dominant, due to their relatively low
cost, high sensitivity and stability [4]. An alternative type
of RDT detects the enzyme parasite lactate dehydrogenase
(pLDH) which is produced by all four human Plasmodium
species. Although HRP2-based tests are generally more
sensitive than pLDH-based tests, the relatively low level of
specificity in diagnosing clinical malaria of HRP2-based
tests is a cause for concern [5]. This reflects the fact that
HRP2 can persist in the blood stream for several weeks,
resulting in high false positive error rates among patients
with cleared parasitaemia who seek treatment for illnesses
other than malaria [6]. A high number of false positives
can compromize the cost-effectiveness of these tests.
There is little information on the epidemiological factors
that influence the specificity of HRP2-based tests. In the
present study, we assessed the sensitivity, specificity, pos-
itive predictive value (PPV) and negative predictive value
(NPV) of RDTs compared with expert microscopy in two
different malaria transmission settings. Diagnostic per-
formance was analysed by age group, month of presenta-
tion and according to a number of patient-related
characteristics and a statistical model was used to investi-
gate the effects of different factors on false positive error
rates. Differences in the positivity rates of RDTs across
highland sites with varying transmission levels and in dif-
ferent months were also investigated. The implications of
the findings are explored in relation to disease manage-
ment in different areas with varying endemicity. Possible
ramifications of the findings in terms of interpretation of
cost-effectiveness analyses and accuracy of malaria sur-
veillance data generated from the use of HRP2-based tests
are discussed.
Materials and methods
The results reported in this paper were obtained during
the course of two studies undertaken as components of a
large epidemic surveillance project conducted in four
highland districts of Kenya and Uganda [7,8].
Longitudinal study
One of the two studies involved longitudinal monitoring
of factors influencing malaria transmission undertaken in
four sites at varying altitude where meteorological, ento-
mological, clinical and parasitological data were collected
concurrently over a period of approximately four years.
The two sentinel sites in Uganda were Bufundi Health
Centre (29°52' E, 1°17'S; elevation 2291 m) in Kabale
District and Kebisoni Health Centre (30°01' E, 0°51' S;
elevation 1670 m) in Rukungiri District. Bufundi has a
cool climate whereas Kebisoni is characterized by a mild
climate. Both areas have two rainy seasons: March-April
and September-November. Temperatures are highest in
February and between June and August. Many inhabitants
in Bufundi are subsistence farmers who often also travel to
neighbouring districts to work as migrant labourers in
large farms. Inhabitants of Kebisoni are relatively seden-
tary farmers. The two study sites in Kenya were Sengera
and Kilibwoni Health Centres, located in Gucha and
North Nandi Districts, respectively. Sengera (34°43'E,
0°52'S; elevation 1816 m) is the only non-governmentalMalaria Journal 2008, 7:202 http://www.malariajournal.com/content/7/1/202
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health centre among the four sites and has a mild climate.
Kilibwoni (35°14'E, 0°13'N; elevation 2065 m) is charac-
terized by a cool and wet climate suitable for growing tea,
which is a significant cash crop in the area. In both Ken-
yan study areas, peak temperatures occur during February
and March and the two rainy seasons are April-June and
September-December.
At each study health centre, patients diagnosed clinically
as a case of malaria according to standard national proce-
dures for case management were subsequently tested
using the Paracheck Pf® test (Orchid Biomedical Systems,
Goa, India) over approximately four years between
November 2002 and September 2006 (except in Gucha
where the study terminated in May 2006). The devices
were stored at room temperatures within the range recom-
mended by the manufacturer and used within the dura-
tion of the recommended shelf life of 24 months. The
proper storage and use of the devices were ensured by
supervisory staff at each site. The devices were purchased
six times during the study period directly from the same
manufacturer at the same time for both countries, but no
attempt was made to use similar batches in all sites at sim-
ilar times due to substantial variations in rates of use
between sites and due to unpredictable nature of patient
numbers. In a few cases, devices stored at sites with lower
rates of use were transferred to other sites with higher
rates. Clinical diagnosis of malaria was made usually by
clinical officers on the basis of presence of fever or history
of fever and absence of any other obvious cause of fever.
Ethical approval for the study was obtained from relevant
authorities in each country and from the London School
of Hygiene and Tropical Medicine. Laboratory staff were
given training on how to undertake RDT tests and on how
to interpret the test results according to the manufacturer's
instructions. Patients were asked by laboratory staff about
any history of travel during the previous two weeks and
about the use of antimalarials prior to the visit. Axillary
temperature was measured using a digital thermometer.
All patients diagnosed clinically as malaria cases were
treated according to national guidelines irrespective of the
outcome of the RDTs. The antimalarials used at the time
of the study were a chloroquine and sulphadoxine-
pyrimethamine (SP) combination in Uganda, and SP and
later amodiaquine in Kenya.
Studies of the sensitivity and specificity of RDTs
Studies to determine the sensitivity and specificity of the
HRP2-based RDTs in comparison with expert microscopy
were carried out at Kebisoni (Uganda) and Kilibwoni
(Kenya) between December 2005 and March 2006 (a
transmission season in both sites). These sites were
selected because of their similarly sedentary populations
and the fact that they were both government facilities,
while they differed markedly in altitude and malaria ende-
micity. Finger-prick blood samples were taken from all
clinically diagnosed malaria cases for both microscopic
examination and RDTs. Verbal consent of patients or
guardians was requested before taking blood samples.
Thin and thick blood films were prepared and filter paper
samples obtained for molecular studies (not reported in
the present paper). Giemsa staining was used according to
standard procedures. Slides were examined until 200
white blood cells (WBCs) were counted if positive. Slides
for which parasites were not detected after counting up to
200 WBCs were examined until 400 WBCs were counted
before a slide was considered to be negative. Parasite den-
sity per microlitre of blood was estimated by multiplying
the counts by 8,000 (the approximate number of WBCs
per microlitre) and dividing the result by the WBC counts.
Duplicate slides were examined independently by two
experienced microscopists who were blinded to the RDT
results. In the case of a discrepant result, a third micro-
scopist re-examined both slides. Results from the third
microscopist were considered final.
Data analysis
Microsoft Access version 2000 (Microsoft Corporation,
Seattle, USA) was used for data entry. Stata Version 10
(StataCorp, College Station, Texas, USA) was used for data
analysis. The sensitivity, specificity, PPV and NPV of the
RDTs were compared between the two areas, across differ-
ent age groups and months covering the transmission
period. A logistic regression model was used to study the
effects of variations in patient characteristics (sex, age,
presence of fever, travel history, prior intake of antimalar-
ials as reported by patient or guardian, and prior visit to
the health facility), month of presentation, and geograph-
ical area on the specificity of RDTs. The variable of interest
was false positive RDT test results among microscopically
confirmed negative tests.
Results
Variations in RDT positivity rate by site
A total of 78,454 patients with a clinical diagnosis of
malaria were tested using RDTs over a period of approxi-
mately four years at four study health centres; 25,473
(32.5%) tested positive for P. falciparum malaria. Bufundi
and Kilibwoni, both located at relatively high altitude,
had lower RDT positivity rates compared to Kebisoni and
Sengera (Table 1). Positivity rate increased with decreas-
ing altitude. Sites located at high altitudes showed similar
positivity rates among all age groups (Figure 1) except for
increased rates in males aged 15 years and above at
Bufundi, which probably reflects high levels of mobility
in this group due to seasonal labour in neighbouring (and
more endemic) districts. Some variations in morbidity
levels between age groups were observed in Sengera and
Kebisoni, areas located at lower altitudes. Sengera, which
is a non-governmental health centre, showed an age pat-Malaria Journal 2008, 7:202 http://www.malariajournal.com/content/7/1/202
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tern compatible with moderately high endemicity in
which relatively few adults are affected compared with
younger age groups.
RDT positivity rates varied by season and year at each site,
indicating temporal changes in accuracy of clinical diag-
nosis of malaria (Figure 2). The absolute number of sus-
pected cases of malaria who tested positive varied
between sites depending on altitude and type of health
facility. As an example, Sengera, the non-governmental
facility, charged fees for consultation and drugs whereas
the other government facilities provided free treatment,
resulting in relatively low observed attendance at the facil-
ity.
RDT positivity rates increased as the number of RDT-pos-
itive cases increased, especially in sites located at lower
altitudes. There was a strong correlation between monthly
RDT positivity rates at four sentinel sites in Uganda and Kenya, October 2002 – September 2006, by gender and age group  (key: dark and grey bars represent males and females, respectively) Figure 1
RDT positivity rates at four sentinel sites in Uganda and Kenya, October 2002 – September 2006, by gender 
and age group (key: dark and grey bars represent males and females, respectively).
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Table 1: Altitude, annual climate, malaria incidence rates (estimated from the number of RDT-positive cases who were residents of 
the locality where each health centre is located and using the population of the locality as denominator) and RDT positivity rates at 
the four sentinel sites in Uganda and Kenya*.
Site Altitude 
(m)
Average temperature 
(°C)
Average annual rainfall 
(mm)
Malaria incidence rates 
per 1000 per year
Overall RDT positivity rate 
(%)
Bufundi, Uganda 2291 16.1 884 15.6 5.8
Kilibwoni, Kenya 2065 17.0 1,424 43.2 7.9
Sengera, Kenya 1816 18.9 1,709 3.4 42.2
Kebisoni, Uganda 1670 20.1 1,007 359.8 52.3
*Patients who had a travel history in the two weeks before the tests were done were excluded from the data presented in the table.Malaria Journal 2008, 7:202 http://www.malariajournal.com/content/7/1/202
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RDT positivity rates and number testing positive with
RDTs in all sites, with correlation coefficients varying
between 0.64 (Kebisoni) and 0.87 (Sengera). At Kebisoni,
both clinical malaria cases and RDT-positive cases
increased during the study period, but there was no simi-
lar trend in the RDT positivity rate (Figure 2).
Accuracy of RDTs compared to expert microscopy
At the hypoendemic site (Kilibwoni), only 10/1,000
(1.0%) of cases examined microscopically were positive
for P. falciparum by RDT, whereas at the mesoendemic site
(Kebisoni), 609/1,237 (49.2%) were positive. The sensi-
tivity, specificity, PPV and NPV of the RDTs at Kilibwoni
were 90.0%, 99.9%, 90.0% and 99.9%, respectively,
whereas the corresponding figures at Kebisoni were
91.0%, 65.0%, 71.6% and 88.1%, respectively. A signifi-
cantly higher specificity was observed at Kilibwoni com-
pared to that of the more endemic Kebisoni (p < 0.0001)
(Figure 3). This resulted in a significantly higher NPV for
RDTs in the former (p < 0.0001), but there was no signif-
icant difference between the two sites in terms of PPV (p =
0.198). At Kebisoni, 220/628 patients (35%) who tested
negative by microscopy tested positive by RDT. At Kilib-
woni, only one of the 990 patients who tested negative by
microscopy tested positive by RDT. Fifty-five of the 609
patients (9%) confirmed to be positive with microscopy
at Kebisoni were declared negative with RDTs. Most of
these patients had low mean parasite densities (below
1,000/μl in 34/55). However, six of the 55 false negative
patients at Kebisoni (11%) had parasite densities exceed-
Longitudinal variations in number tested (grey bars), RDT positive cases (solid line) and the corresponding RDT positivity rates  (dashed line) at four sites in Kenya and Uganda between November 2002 and August 2006 Figure 2
Longitudinal variations in number tested (grey bars), RDT positive cases (solid line) and the corresponding 
RDT positivity rates (dashed line) at four sites in Kenya and Uganda between November 2002 and August 
2006. Patients with a travel history in the previous two weeks before presentation were excluded. All patients clinically diag-
nosed as malaria cases were subsequently tested with RDTs, except in Kilibwoni between January 2003 and February 2004 
when approximately 50% were tested.
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ing 8,000/μl. At Kilibwoni, one patient was false negative
by RDT out of a total of 10 who were confirmed positive
by microscopy.
At Kebisoni, true parasite rates (as determined by micros-
copy) declined during the four months (December 2005
– March 2006) of concurrent collection of blood samples
for comparison of RDTs with microscopy. During this
period, the specificity of RDTs increased steadily from
56% in December 2005 to 79% in March 2006 (Figure
4a). There was no substantial change in the sensitivity of
RDTs. During the same period, the NPV of RDTs increased
from 67% to 92% whereas there was little change in PPV
(76% in December 2005 and 77% in March 2006).
The true parasite rate varied between age groups. The peak
parasite rate was observed in children 2–4 years of age and
the rate decreased in the older age groups (Figure 4b). Spe-
cificity of RDTs increased as parasite rates decreased, but
sensitivity was more or less uniform among the various
age groups.
Sensitivity of RDTs was significantly higher in patients
with fever (body temperature of 37.5°C and above) on
presentation compared to non-febrile patients (97% ver-
sus 89%, p = 0.006) but specificity was significantly lower
in febrile patients (33% versus 69%, p < 0.0001). No sig-
nificant differences were detected between the two groups
in terms of PPV and NPV (p = 0.827 and p = 0.742, respec-
tively). At Kebisoni, microscopically confirmed P. falci-
parum  patients with high parasite densities were
significantly more likely to be true positive with RDTs
than patients with a low parasite density (Figure 5). The
mean parasite densities of false negatives and true posi-
tives were 898/μl and 5,215/μl and this difference was sta-
tistically highly significant (p < 0.0001).
A logistic regression model showed that age, presence of
fever, area and month of presentation were significantly
and independently associated with probability of a nega-
tive RDT test result being a true negative (Table 2). False
positive error rates declined in older age groups. Patients
with fever at the time of presentation were more likely to
test false positive with RDTs compared to those without.
The site at higher altitude and with low malaria transmis-
sion intensity was associated with higher specificity. Spe-
cificity increased towards the end of the transmission
season. Previous intake of antimalarials, revisit in the pre-
vious two weeks, travel outside the district in the previous
two weeks and sex were not significantly associated with
Sensitivity, specificity, PPV and NPV of RDTs compared to microscopy in Kebisoni (mesoendemic area) and Kilibwoni (hypoen- demic area) Figure 3
Sensitivity, specificity, PPV and NPV of RDTs compared to microscopy in Kebisoni (mesoendemic area) and 
Kilibwoni (hypoendemic area). Error bars indicate 95% confidence intervals.
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the probability of a negative RDT test result being true
negative.
Discussion
This study showed that in an area with moderate malaria
transmission, more than a third of patients with positive
HRP2-based RDT tests had a negative blood film and may
have been incorrectly diagnosed as a case of clinical
malaria due to persistence of the HRP2 antigen from an
earlier infection. It is possible that a few patients with sub-
microscopic or low levels of parasitaemia might have
been wrongly classified as negative with microscopy.
However this number is likely to have been very small as
blood films were read carefully by two experienced micro-
scopists. In contrast, nearly all RDT positive patients in a
site with low endemicity were true positives. False positive
error rates declined with increasing age of patients, prob-
ably as the result of acquired immunity in clearing para-
site antigens. Previous studies have shown that HRP2-
based RDTs can lead to high false positive error rates.
Swarthout et al reported that by using Paracheck-Pf®, 73%
of cases were still RDT test positive 35 days after treatment
and that the false positive error rate correlated with initial
parasite density [6]. Iqbal et al found nearly 35% of
patients still had HRP2 antigenaemia 14 days after treat-
ment despite negative blood films [9]. In another study,
61% of patients had positive HRP2-based RDT tests for
more than two weeks after initiation of treatment [10].
These antigens are eventually cleared by anti-HRP2 anti-
bodies, especially anti-HRP2 IgG [11].
The study also showed that the specificity of RDTs varied
seasonally in the same area. At the mesonendemic site
(Kebisoni), specificity increased as the true parasite rate
(as determined by microscopy) decreased at the end of the
transmission season. This may have followed from boost-
ing of anti-HRP2 antibodies as a result of infections
acquired during the preceding few months. The relatively
higher specificity of RDTs at the hypoendemic site com-
pared with the mesoendemic site could, on the other
hand, be due to a very low probability of finding patients
with recently cleared parasitaemia who sought treatment
for non-malarial illnesses.
Sensitivity of RDTs was not affected by age of patient or
fluctuation in parasite rates during different months. It
was, however, affected by parasite density. Patients with
high parasite densities were more likely to test positive
Sensitivity and specificity of RDTs as a function of the true parasite rate (as determined by microscopy) at Kebisoni, Rukungiri  District, Uganda, by (a) month and (b) age groups (error bars indicate 95% confidence intervals) Figure 4
Sensitivity and specificity of RDTs as a function of the true parasite rate (as determined by microscopy) at 
Kebisoni, Rukungiri District, Uganda, by (a) month and (b) age groups (error bars indicate 95% confidence 
intervals).
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Differences in parasite densities between false negative and true positive RDT results compared to microscopy at Kebisoni,  Uganda Figure 5
Differences in parasite densities between false negative and true positive RDT results compared to micros-
copy at Kebisoni, Uganda.
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Table 2: Outputs of the best-fitting logistic regression model for factors associated with the probability of obtaining true negative 
HRP2-based RDT test results at Kebisoni, Uganda. 
Factors Odds ratio Standard error P
Area (Kebisoni relative to baseline = Kilibwoni) 0.002 0.002 < 0.0001
Age (years) 1.017 0.005 0.002
Presence of fever at the time of presentation 
(relative to baseline = absence of fever at the time of presentation)
0.275 0.073 < 0.0001
January (relative to baseline = December)* 1.173 0.367 0.609
February (relative to baseline = December)* 1.414 0.458 0.285
March (relative to baseline = December)* 2.623 1.026 0.014
Previous intake of antimalarials, a clinic visit in the previous two weeks, travel outside the district in the previous two weeks and sex were not 
significantly associated with the dependent variable.
* Significance of the combined effect of months: Chi-squared at 3 degrees of freedom = 8.57, p = 0.0356.Malaria Journal 2008, 7:202 http://www.malariajournal.com/content/7/1/202
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than those with low parasitaemia. Other studies have also
indicated that HRP2-based tests have high sensitivity
which increases with parasite density [3]. However, sensi-
tivity can vary from area to area. There are variations in the
repeat section of the HRP2 protein between parasite iso-
lates from different areas which might be a reason for
wide variations in sensitivity of HRP2-based RDTs in dif-
ferent areas [12]. A study carried out in Uganda showed
that the PPV was only 20% at a site of low endemicity (in
Kabale District) whereas in other areas with higher ende-
micity it was much higher, while the NPV was uniformly
high (> 97%) [13]. In the present study, estimates of both
the PPV and NPV were high at the site with low endemic-
ity in Kenya. Although it has been suggested in one study
that sensitivity is affected by age-dependent immune sta-
tus of patients independent of parasite density [14], no
evidence of this phenomenon was found in the present
study.
It might be argued that some of the variability observed
between the sites and during different parts of the year
could have resulted from performance variability of the
tests used, especially as climatic conditions affect the sta-
bility of the devices. Stability is usually more problematic
with pLDH-based tests than with HRP2-based tests. Due
to variable rates of use in different sites, the use of similar
batches of the tests across all sites and seasons could not
be ensured. Nevertheless, the devices were purchased at
the same times for both countries, and from the same
manufacturer during the entire study period. The devices
were also stored and used within the recommended tem-
perature and duration. Due to these and the fact that the
sensitivity of the tests in Kenya and Uganda were similar
(90.0% and 91.0%, respectively), variability in perform-
ance of the devices is unlikely to have played a major role.
The use of RDTs is probably cost-effective in many situa-
tions. A simulation study has indicated that at a 95% con-
fidence level, RDTs are cost-effective compared to
presumptive treatment below 62% parasite prevalence
rates [2]. However, cost-effectiveness of RDTs can be com-
promized if patients with negative RDT tests are pre-
scribed antimalarials [15] as has been shown in both
Tanzania [16] and Zambia [17] to frequently be the case.
A danger of reliance on RDTs is that some patients who
require malaria treatment may test negative and be given
symptomatic treatment only. In this study, the fact that
there were 9% false negative RDT tests among microscop-
ically confirmed cases at Kebisoni, some of whom had
high parasitaemia, shows the risk of relying on test results
alone. Due to potential variations in the accuracy of RDTs
by season, as suggested by the present study, seasonal use
of these diagnostic tools may be necessary after careful
cost-effectiveness studies in some areas, especially those
with mesoendemic transmission.
During an epidemic caused by flooding in Mozambique,
RDTs were shown to have an adequate PPV when com-
bined with clinical diagnosis, although they failed to
detect some true malaria cases [18]. Thus, the use of RDTs
for treatment decisions in epidemics could increase the
risk of missed treatment. Furthermore, the cost-effective-
ness of using RDTs during epidemics is unclear. For exam-
ple, one study showed that the percentage of confirmed
malaria cases must not exceed 55% for RDTs to be cost-
effective when artemether-lumefantrine is used for treat-
ment [19]. The threshold level for artesunate-amodi-
aquine was even lower (21%). During epidemics, the
proportion of fever cases who test positive can increase
considerably in a short period of time.
Although the use of RDTs for treatment decisions in epi-
demic situations may be limited, their use can be helpful
in surveillance, for example in the confirmation of
reported outbreaks. However, RDT-based longitudinal
data should be interpreted with caution due to potential
seasonal or annual variations in accuracy resulting from
temporal changes in transmission levels as indicated in
this study. The study also shows that data generated from
clinical diagnosis alone could be useful in epidemic mon-
itoring, in particular in mesoendemic situations. How-
ever, in highlands with very low endemicity, the use of
clinical data alone without laboratory confirmation can
be misleading. This was observed in Bufundi, in Uganda,
where an apparent outbreak of clinical malaria was con-
firmed to be a non-malarial febrile illness [8].
One of the major implications of the findings of the
present study is that cost-effectiveness of HRP2-based
RDTs is greatly influenced by variations in their sensitivity
and specificity between different areas, age groups of
patients, and seasons. The study showed that the diagnos-
tic accuracy of HRP2-based RDTs is relatively high in areas
or seasons with low transmission, but more area-specific
operational studies may be required to evaluate their cost-
effective use under different transmission scenarios. For
decisions involving the use of these tests, policymakers
should take into account the cost implications of treating
test negative patients [15], as well as the risk of not treat-
ing false negative patients. The cost-effectiveness of HRP2-
based RDTs depends on a multitude of factors: overall
diagnostic accuracy, prevalence and its seasonal fluctua-
tions, seasonal changes in test specificity, age group of
study subjects, parasite density, the relative cost of anti-
malarials and RDT tests, the relative treatment costs of test
negative cases and the extent to which clinicians trust the
outcomes. RDT test results should always be interpreted
together with clinical assessment of the patient, allowing
for fallibility of the devices [20]. In some vulnerable
patients (e.g. children), the risk of leaving a false-negative
case untreated for malaria may outweigh the costs of overMalaria Journal 2008, 7:202 http://www.malariajournal.com/content/7/1/202
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treatment based on clinical diagnosis [4]. Authorities in
charge of developing malaria diagnostic policies may have
to interpret reports on specificity of HRP2-based RDTs
and cost-effectiveness analyses on their use with some
caution as there may be wide variations in the determi-
nant factors of accuracy between different studies. In some
areas, it may be useful to vary the use of HRP2-based RDTs
according to factors such as transmission level, season and
age group of patients, but such policies should be based
on further area-specific investigations. Especially in situa-
tions where the diagnostic accuracy of RDTs is unlikely to
be high, health services will need to strengthen micros-
copy.
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